Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Collaboration focuses on developing a KRAS G12D inhibitor, complementing Bayer’s precision oncology development portfolio in the areas of pancreatic, ...

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combinat ...

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), ...

The US Food & Drug Administration's (FDA) resources have been cut more times than Martin Scorsese’s then-edgy 1988 religious ...

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced ...

Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked ...

Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in ...

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

A new tool from the lab of Velia Therapeutics co-founder Alan Saghatelian, Ph.D., has proven capable of scouring genetic data for tiny proteins that may serve as new therapeutic targets, opening the ...

The guidelines, based on research published in the AHA's Circulation journal, say that cutting back on these foods reduces a person's risk of having a heart attack, a stroke, type 2 diabetes and ...